Jerome Alexandre
Overview
Explore the profile of Jerome Alexandre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
4137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Minot-This M, Boudou-Rouquette P, Jouinot A, De Percin S, Balakirouchenane D, Khoudour N, et al.
Pharmaceutics
. 2022 Jun;
14(6).
PMID: 35745797
Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed...
22.
Rousseau A, Laune Q, Ollivier L, Naoun N, Alexandre J, Giraud P, et al.
Bull Cancer
. 2022 Jun;
109(7-8):834-843.
PMID: 35672186
Background: COVID-19 pandemic troubled hospital and university's organization. Previous study showed oncology resident's formation has been impacted by pandemic. One year later, we aimed to evaluate the state of oncology...
23.
Gorgeu V, Borghese B, Koual M, Just P, Lefrere Belda M, Delanoy N, et al.
Gynecol Oncol
. 2022 Jun;
166(2):269-276.
PMID: 35643579
Introduction: Adjuvant therapeutic decisions in older endometrial carcinoma (EC) patients are challenged by a balance between more frequent aggressive EC and comorbidities. We assessed whether EC and comorbidities are competing...
24.
Castel-Ajgal Z, Goulvestre C, Zaibet S, Arrondeau J, Bretagne M, Peyromaure M, et al.
Clin Genitourin Cancer
. 2022 May;
20(5):e362-e368.
PMID: 35577731
Introduction: Immune checkpoint inhibitor are standard therapy in metastatic urothelial carcinoma. No predictive biomarker of immune related adverse events (iRAE) exists. Antinuclear antibodies (ANA) can be the sign of a...
25.
Beinse G, Borghese B, Metairie M, Just P, Poulet G, Garinet S, et al.
Clin Chem
. 2022 Mar;
68(6):782-793.
PMID: 35323926
Background: No circulating biomarker is available for endometrial carcinoma (EC). We aimed to identify DNA positions universally hypermethylated in EC, and to develop a digital droplet PCR (ddPCR) assay for...
26.
Fumet J, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267497
Background: Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment...
27.
Alexandre J, Ray-Coquard I, Joly F
JCO Precis Oncol
. 2022 Jan;
4:1025-1026.
PMID: 35050765
No abstract available.
28.
Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer
Beinse G, LE Frere Belda M, Just P, Bekmezian N, Koual M, Garinet S, et al.
Gynecol Oncol
. 2022 Jan;
164(3):596-606.
PMID: 35033379
Background: Despite recent advances in endometrial carcinoma (EC) molecular characterization, its prognostication remains challenging. We aimed to assess whether RNAseq could stratify EC patient prognosis beyond current classification systems. Methods:...
29.
Selle F, Alexandre J, Prulhiere K, Kalbacher E, Ray-Coquard I, Leary A
Bull Cancer
. 2021 Dec;
108(9S1):S5-S12.
PMID: 34955161
In early stages, standard treatment is adjuvant chemotherapy, consisting of platinum-based combination for 6 cycles, especially in serous and endometrioid high grade carcinomas. In advanced stages, indication of neoadjuvant chemotherapy...
30.
Vigneron C, Charpentier J, Valade S, Alexandre J, Chelabi S, Palmieri L, et al.
Ann Intensive Care
. 2021 Dec;
11(1):182.
PMID: 34951668
Background: Major therapeutic advances including immunotherapy and targeted therapies have been changing the face of oncology and resulted in improved prognosis as well as in new toxic complications. The aim...